Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer
about
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.Immune checkpoint inhibitor combinations in solid tumors: opportunities and challengesDo immune checkpoint inhibitors need new studies methodology?
P2860
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Moving towards a customized ap ...... oint inhibitors in lung cancer
@ast
Moving towards a customized ap ...... oint inhibitors in lung cancer
@en
Moving towards a customized ap ...... oint inhibitors in lung cancer
@nl
type
label
Moving towards a customized ap ...... oint inhibitors in lung cancer
@ast
Moving towards a customized ap ...... oint inhibitors in lung cancer
@en
Moving towards a customized ap ...... oint inhibitors in lung cancer
@nl
prefLabel
Moving towards a customized ap ...... oint inhibitors in lung cancer
@ast
Moving towards a customized ap ...... oint inhibitors in lung cancer
@en
Moving towards a customized ap ...... oint inhibitors in lung cancer
@nl
P2093
P2860
P50
P1476
Moving towards a customized ap ...... oint inhibitors in lung cancer
@en
P2093
Federica Cuppone
Giampaolo Tortora
Niki Karachaliou
Rafael Rosell
Sandra Petraglia
P2860
P304
P356
10.3978/J.ISSN.2218-6751.2015.10.08
P407
P577
2015-12-01T00:00:00Z